Key Points
- CEO Helen Torley sold 20,000 Halozyme shares at an average price of $109.40, generating $2.19 million. The sale occurred under a pre-arranged Rule 10b5-1 plan and reduced her holdings by 2.54%.
- Halozyme reported stronger-than-expected quarterly results, with EPS of $2.28 versus the $1.79 consensus estimate and revenue of $481 million, up 47.7% year over year. The company guided to fiscal 2026 EPS of $8.65–$9.00.
- The company received favorable developments for its ENHANZE platform, including a Dutch court ruling against Merck’s subcutaneous Keytruda in several European markets and an expanded collaboration with argenx. However, analysts’ consensus remains “Moderate Buy,” while JPMorgan’s $78 target implies substantial downside from the referenced $109.84 share price.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $83,995,132. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.58, for a total transaction of $2,191,600.00.
- On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00.
- On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.24, for a total transaction of $2,144,800.00.
- On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00.
Halozyme Therapeutics Price Performance
Shares of NASDAQ:HALO opened at $109.84 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $116.85. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The company has a market cap of $12.47 billion, a PE ratio of 32.79, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88. The company's 50 day moving average is $105.64 and its 200 day moving average is $82.86.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm's revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.
Institutional Trading of Halozyme Therapeutics
Several institutional investors have recently bought and sold shares of HALO. Bank of America Corp DE purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $214,504,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth $196,540,000. Congress Asset Management Co. increased its holdings in Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock worth $251,890,000 after acquiring an additional 1,052,509 shares in the last quarter. Royal London Asset Management Ltd. raised its position in Halozyme Therapeutics by 12.4% during the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company's stock worth $141,732,000 after acquiring an additional 200,262 shares during the period. Finally, First Trust Advisors LP lifted its holdings in Halozyme Therapeutics by 46.5% during the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company's stock valued at $95,804,000 after purchasing an additional 470,558 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
HALO has been the subject of several recent research reports. Weiss Ratings upgraded Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, August 31st. Citigroup reaffirmed a "market outperform" rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a "neutral" rating in a report on Thursday. TD Cowen raised their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $94.00.
Read Our Latest Stock Report on Halozyme Therapeutics
Key Stories Impacting Halozyme Therapeutics
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: A Dutch patent court found Merck’s subcutaneous Keytruda infringed a Halozyme patent and ordered MSD to stop manufacturing, selling, importing, or stocking the product in eight European markets: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The ruling could protect Halozyme’s intellectual-property position and potential royalty economics. Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
- Positive Sentiment: Halozyme expanded its ENHANZE collaboration with argenx to cover two additional exclusive targets, bringing the total to eight. The agreement increases the opportunity for future development milestones and royalties and supports Halozyme’s recurring revenue growth. HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
- Neutral Sentiment: The Keytruda decision is a significant win, but the ongoing patent dispute, possible appeals, and the timing of any commercial impact create uncertainty around how quickly the ruling will translate into financial results.
- Negative Sentiment: JPMorgan raised its HALO price target from $70 to $78 but maintained a “neutral” rating. The new target implies roughly 29% downside from the referenced $109.84 price, signaling concern that the stock’s valuation already reflects much of its growth and legal upside. JPMorgan Raises Halozyme Price Target
Halozyme Therapeutics Company Profile
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.
Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
